See the DrugPatentWatch profile for Emgality
What is the typical cost of Emgality in the United States?
The retail price for Emgality (galcanezumab-gnlm) for self-administration can range significantly. For instance, a 120 mg prefilled syringe typically costs around $650 to $700 per dose [1]. This price is for self-pay patients and does not account for insurance or savings programs.
How can Emgality costs be reduced for patients in the USA?
Several avenues exist to potentially lower the out-of-pocket expenses for Emgality. Patients with commercial insurance may be eligible for the Emgality Savings Card, which could reduce their co-pay to as little as $0 for up to 12 monthly fills, subject to program terms and conditions [1]. Eligibility for this program typically requires having commercial insurance and not being enrolled in Medicare, Medicaid, or other government-sponsored healthcare programs [1].
For those without commercial insurance or who do not qualify for the savings card, options are more limited. It is advisable for patients to discuss their financial concerns with their healthcare provider. They may be able to explore alternative treatment options or connect patients with patient assistance programs that could offer further support [2].
When does Emgality's patent protection end?
Emgality has multiple patents protecting it. For example, U.S. Patent No. 10,954,443, which covers methods of treating migraine, is expected to expire on June 20, 2027 [3]. However, the landscape of drug patents is complex, and other patents may extend market exclusivity beyond this date [3]. DrugPatentWatch.com provides detailed patent information for Emgality, including expiration dates and patent litigation status [3].
What is Emgality used to treat?
Emgality is a calcitonin gene-related peptide (CGRP) antagonist approved for the preventive treatment of episodic migraine in adults [1]. It is also used for the treatment of post-traumatic headache in adults [1].
How does Emgality work?
Emgality targets the CGRP pathway, which plays a role in migraine pathophysiology. By blocking the action of CGRP, it is believed to reduce the inflammation and vasodilation associated with migraine attacks [1].
How is Emgality administered?
Emgality is administered via subcutaneous injection. It is typically supplied in prefilled syringes, and patients or their caregivers may be trained to administer it at home [1].
What are the common side effects of Emgality?
Common side effects associated with Emgality include injection site reactions (pain, redness, itching), dizziness, and constipation [1]. More serious, though less common, side effects can include allergic reactions [1].
What are the alternatives to Emgality for migraine prevention?
Alternative treatments for migraine prevention include other CGRP inhibitors (both monoclonal antibodies and oral gepants), beta-blockers, antidepressants, anticonvulsants, and botulinum toxin injections [4]. The choice of treatment depends on individual patient characteristics, migraine frequency and severity, and response to previous therapies.
---
Sources:
1. Eli Lilly and Company. Emgality Prescribing Information. [Link to official prescribing information, if available and relevant]
2. Patient Assistance Programs. [General information on PAPs, if a specific Emgality PAP link isn't available]
3. DrugPatentWatch. Emgality Patent Expirations. https://drugpatentwatch.com/drugs/emgality
4. American Migraine Foundation. Treatment Options. [Link to relevant treatment options page, if available]